ArticleTheranostics2017
Clinical Translation and First In-Human Use of [
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 140 citations in OpenAlex.
- DOTAM-TCB: Universal Small Molecule-guided Hapten- and T Cell-bispecific Antibodies for Cancer Immunotherapy.Antibody therapeutics · 2026Article
- First ex-vivo positronium imaging of tissues with modular J-PET scanner usingZeitschrift fur medizinische Physik · 2026Article
- Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026Review
- Radiation stability and performance of TEHDGA resin for theranostic scandium radionuclide purification.EJNMMI radiopharmacy and chemistry · 2026Article
- Investigating the Theranostic Potential of Elementally Matched [Molecular pharmaceutics · 2026Article
- Investigation of aBMC cancer · 2026Article
- Evaluation of Bifunctional, PSMA-Targeted Triazamacrocycle-Picolinates Compatible with theJournal of medicinal chemistry · 2025Article
- Sc(III) Complexes of Pyclen Derivative Ligands as Probes for Hypoxia: Synthesis, Chemical Characterization,Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- First positronium lifetime imaging with scandium-44 on a long axial field-of-view PET/CT.Frontiers in nuclear medicine · 2025Article
- Fast high-resolution lifetime image reconstruction for positron lifetime tomography.Communications physics · 2025Article
- Production of high purityEJNMMI radiopharmacy and chemistry · 2024Article
- Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlightingEJNMMI physics · 2024Article
- Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours.EJNMMI physics · 2024Article
- Evaluation of Prostate-Specific Membrane Antigen (PSMA) Immunohistochemical Expression in Early-Stage Breast Cancer Subtypes.International journal of molecular sciences · 2024Article
- Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues.International journal of molecular sciences · 2024Review
- In Vivo Imaging of Acute Hindlimb Ischaemia in Rat Model: A Pre-Clinical PET Study.Pharmaceutics · 2024Article
- Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.Inorganic chemistry · 2023Article
- Metal-Ligand Interactions in Scandium Complexes with Radiopharmaceutical Applications.Inorganic chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [
methodsScandium-44 was obtained from a
resultsQuantitative radiochemical yields of ≥98 % were achieved using 18 nmol of PSMA-617 after 20 min at 95 °C with apparent molar activity of 6.69±0.78 MBq/nmol. Following purification, >99 % radiochemical purity was obtained. [
conclusionIn conclusion [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.